{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.530","value":"1.33"},{"groupId":"OG001","spread":"1.17","value":"1.85"},{"groupId":"OG002","spread":"1.41","value":"1.64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"The accumulation ratio was calculated as a ratio of (Ctrough day28, 3rd injection/Ctrough day28, 1st injection).","dispersionType":"Standard Deviation","groups":[{"description":"Enrolled patients were randomized to 20mg pasireotide LAR.","id":"OG000","title":"Pasireotide LAR 20mg"},{"description":"Enrolled patients were randomized to 40mg pasireotide LAR.","id":"OG001","title":"Pasireotide LAR 40mg"},{"description":"Enrolled patients were randomized to 60mg pasireotide LAR.","id":"OG002","title":"Pasireotide LAR 60mg"}],"paramType":"MEAN","populationDescription":"PAS: Consists of full analysis set (FAS) who have evaluable PK concentration data","reportingStatus":"POSTED","timeFrame":"Day 28 after injections 1 and 3","title":"Summary of Pasireotide LAR PK Parameter of Accumulation Ratio Randomized Dose Level","type":"SECONDARY","unitOfMeasure":"ratio"}